French (CAC) Pharma Industry Analysis

UpdatedMar 07, 2026

DataAggregated Company Financials

Companies6

7D-6.6%
3M-6.4%
1Y-24.5%
YTDn/a

Over the last 7 days, the Pharma industry has dropped 3.2%, driven by a pullback from Sanofi of 3.9%. Overall the industry is down 23% in 12 months. Looking forward, earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the French Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sat, 07 Mar 2026	€109.9b	€54.0b	€5.4b	21.8x	20.4x	2x
Mon, 02 Feb 2026	€111.7b	€53.8b	€5.5b	22.1x	20.4x	2.1x
Wed, 31 Dec 2025	€115.5b	€53.0b	€7.0b	21.8x	16.6x	2.2x
Fri, 28 Nov 2025	€119.5b	€53.0b	€7.0b	22.8x	17.2x	2.3x
Sun, 26 Oct 2025	€122.8b	€53.0b	€7.0b	22.4x	17.6x	2.3x
Tue, 23 Sep 2025	€111.5b	€52.8b	€6.9b	19.8x	16.1x	2.1x
Thu, 21 Aug 2025	€120.1b	€52.8b	€6.9b	19.7x	17.3x	2.3x
Sat, 19 Jul 2025	€114.6b	€52.1b	€6.7b	20.4x	17.2x	2.2x
Mon, 16 Jun 2025	€118.5b	€52.1b	€6.7b	18.3x	17.8x	2.3x
Wed, 14 May 2025	€121.9b	€52.1b	€6.7b	17.7x	18.3x	2.3x
Fri, 11 Apr 2025	€120.7b	€51.2b	€5.9b	17.5x	20.3x	2.4x
Sun, 09 Mar 2025	€150.6b	€51.1b	€5.9b	18.4x	25.4x	2.9x
Tue, 04 Feb 2025	€144.4b	€51.1b	€6.3b	18.8x	23x	2.8x
Thu, 02 Jan 2025	€130.9b	€55.2b	€5.1b	18.8x	25.7x	2.4x
Sat, 30 Nov 2024	€128.9b	€55.2b	€5.1b	19.5x	25.3x	2.3x
Mon, 28 Oct 2024	€139.8b	€55.2b	€5.1b	21.1x	27.4x	2.5x
Wed, 25 Sep 2024	€144.4b	€53.9b	€4.8b	21.4x	30.1x	2.7x
Fri, 23 Aug 2024	€137.9b	€53.8b	€4.8b	20.4x	28.7x	2.6x
Sun, 21 Jul 2024	€129.5b	€52.9b	€5.2b	21.2x	25x	2.4x
Tue, 18 Jun 2024	€124.4b	€52.9b	€5.2b	20.7x	24.1x	2.4x
Thu, 16 May 2024	€128.4b	€52.9b	€5.2b	21.3x	24.8x	2.4x
Sat, 13 Apr 2024	€122.1b	€52.7b	€6.0b	20x	20.2x	2.3x
Mon, 11 Mar 2024	€123.1b	€52.6b	€6.0b	20.3x	20.4x	2.3x
Wed, 07 Feb 2024	€123.4b	€53.0b	€6.1b	20.7x	20.4x	2.3x
Fri, 05 Jan 2024	€130.9b	€52.2b	€9.7b	18.4x	13.5x	2.5x
Sun, 03 Dec 2023	€120.8b	€52.2b	€9.7b	17.7x	12.4x	2.3x
Tue, 31 Oct 2023	€119.2b	€52.2b	€9.7b	15.3x	12.3x	2.3x
Thu, 28 Sep 2023	€142.6b	€52.6b	€9.3b	18.3x	15.4x	2.7x
Sat, 26 Aug 2023	€139.0b	€52.6b	€9.3b	21.4x	15x	2.6x
Mon, 24 Jul 2023	€137.5b	€52.6b	€9.1b	18.5x	15x	2.6x
Wed, 21 Jun 2023	€136.5b	€52.6b	€9.1b	15.3x	14.9x	2.6x
Fri, 19 May 2023	€139.4b	€52.6b	€9.1b	15.8x	15.2x	2.6x
Sun, 16 Apr 2023	€141.4b	€51.8b	€9.2b	15.4x	15.4x	2.7x
Tue, 14 Mar 2023	€123.8b	€51.7b	€9.2b	14.9x	13.5x	2.4x

Price to Earnings Ratio

13.5x

Tue, 14 Mar 2023

Current Industry PE

Investors are relatively neutral on the French Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.

The industry is trading close to its 3-year average PE ratio of 19.6x.

The 3-year average PS ratio of 2.4x is higher than the industry's current PS ratio of 2.1x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have declined 16% per year over the last three years.
Meanwhile revenues have remained mostly flat.
This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.